IP Library Granted Patent US 9,932,567
Granted Patent B1
US 9,932,567 · App. 15/406,160 · Granted Apr 3, 2018

Mutant reverse transcriptase

Inventors: Yan Xu (Hamilton, MA); Jennifer Ong (Salem, MA); Shengxi Guan (Stoneham, MA); Nicole Nichols (Reading, MA)
Assignee: New England Biolabs, Inc.
C12N9/22C12N9/1276C12N15/10C12P19/34C12Q1/686C12Y207/07049C12Y301/26004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,932,567
App. No.
15/406,160
Granted
Apr 3, 2018
Kind
B1
Abstract

A mutant MMLV reverse transcriptase that may have an improvement in one or more properties is provided. For example, the present reverse transcriptase is believed to be more efficient relative to other commercially available MMLV reverse transcriptase variants, particularly for templates with a higher GC content.

Claims (18)

1. A method comprising:

(a) obtaining a reaction mix by combining a primer, an RNA template and a reverse transcriptase, wherein the reverse transcriptase comprises: at least 300 contiguous amino acids of SEQ ID NO: 1; and

(b) incubating the reaction mix to produce cDNA copied from the RNA template.

2. The method of claim 1 , wherein the reaction mix is incubated at temperature in the range of 45−60° C.

3. The method of claim 1 , further comprises a template switching oligonucleotide.

4. The method of claim 1 , wherein the primer is an oligo-dT primer.

5. The method of claim 1 , wherein the primer is a random primer.

6. The method of claim 1 , wherein the primer is a gene-specific primer.

7. The method of claim 1 , wherein the reverse transcriptase comprises an exogenous sequence-specific DNA binding domain.

8. The method of claim 1 , wherein the reverse transcriptase comprises an amino acid sequence that is at least 90% identical to at least 300 contiguous amino acids of SEQ ID NO:2 that is C-terminal to the at least 300 contiguous amino acids of SEQ ID NO:1.

9. The method of claim 1 , wherein the reverse transcriptase does not have RNAseH activity.

10. The method of claim 1 , wherein the reverse transcriptase has RNAseH activity.

11. The method of claim 1 , wherein the method comprises: (c) amplifying the cDNA produced in step (b).

12. The method according to claim 11 , wherein the amplification is PCR.

13. The method of claim 1 , wherein the method comprises quantifying the cDNA produced in step (b).

14. A method comprising:

(a) obtaining a reaction mix by combining a primer, an RNA template and a reverse transcriptase, wherein the reverse transcriptase comprises: (i) amino acids 24-335 of SEQ ID NO: 1 and (ii) an amino acid sequence that is at least 90% identical to amino acids 1-286 of SEQ ID NO: 2 wherein the amino acid sequence of (i) is N-terminal to the amino acid sequence of (ii); and

(b) incubating the reaction mix to produce cDNA copied from the RNA template.

Assignments (2)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2017
From: XU, YAN; ONG, JENNIFER; GUAN, SHENGXI; NICHOLS, NICOLE
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 041380/0672 →
Continuity (1)
Continuation 15274622 · Sep 23, 2016